DUBLIN, August 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Asthma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
The increasing availability of biologics will drive growth in the asthma market during 2015-24, but prescribing will be restricted to patients with severe persistent uncontrolled asthma.
This report addresses the following questions:
- Where will the newly approved Nucala and Cinqair be positioned in the treatment algorithm and will they directly compete with Xolair?
- What are pulmonologists' views on the late-phase interleukin (IL) inhibitors and how will they differentiate between them?
- What clinical endpoints do pulmonologists want to see in trial programs of biologics?
- How will the loss of brand exclusivity impact leading inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) inhalers?
Key Topics Covered:
FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU
- Advair (fluticasone/salmeterol)
- benralizumab
- Breo (fluticasone furoate/vilanterol)
- Cinqair (reslizumab)
- Dulera (mometasone/formoterol)
- Flutiform (fluticasone/formoterol)
- Nucala (mepolizumab)
- Singulair (montelukast)
- Spiriva (tiotropium)
- Symbicort (budesonide/formoterol)
- Xolair (omalizumab)
- Primary Research Methodology
TREATMENT: ASTHMA
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Impact of Generics
- Unmet Needs in Asthma
EPIDEMIOLOGY: ASTHMA
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: ASTHMA
- Product profile: Advair
- Product profile: Asmanex
- Product profile: Breo
- Product profile: Cinqair
- Product profile: Dulera
- Product profile: Flovent
- Product profile: Flutiform
- Product profile: Nucala
- Product profile: Pulmicort
- Product profile: Singulair
- Product profile: Spiriva
- Product profile: Symbicort
- Product profile: Xolair
PIPELINE: ASTHMA
- Clinical Pipeline Overview
- Early-Phase Opportunities
- Comparator Therapy
- Clinical Trial Design
- Product profile (late stage): QVM1
- Product profile (late stage): benralizumab
- Product profile (late stage): dupilumab
- Product profile (late stage): lebrikizumab
- Product profile (late stage): masitinib
- Product profile (late stage): tralokinumab
For more information about this report visit http://www.researchandmarkets.com/research/d85tsd/asthma
Related Topics: Asthma Drugs
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article